- Previous Close
193.45 - Open
193.13 - Bid 193.11 x 900
- Ask 194.10 x 800
- Day's Range
191.78 - 195.57 - 52 Week Range
135.85 - 199.95 - Volume
2,474,135 - Avg. Volume
5,189,338 - Market Cap (intraday)
340.798B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
64.53 - EPS (TTM)
2.99 - Earnings Date Oct 25, 2024 - Oct 29, 2024
- Forward Dividend & Yield 6.20 (3.21%)
- Ex-Dividend Date Oct 15, 2024
- 1y Target Est
197.33
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
www.abbvie.com50,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ABBV
View More
Performance Overview: ABBV
Trailing total returns as of 9/18/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABBV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABBV
View MoreValuation Measures
Market Cap
340.80B
Enterprise Value
398.28B
Trailing P/E
64.53
Forward P/E
16.03
PEG Ratio (5yr expected)
0.47
Price/Sales (ttm)
6.22
Price/Book (mrq)
50.28
Enterprise Value/Revenue
7.24
Enterprise Value/EBITDA
22.02
Financial Highlights
Profitability and Income Statement
Profit Margin
9.71%
Return on Assets (ttm)
7.94%
Return on Equity (ttm)
54.26%
Revenue (ttm)
55B
Net Income Avi to Common (ttm)
5.3B
Diluted EPS (ttm)
2.99
Balance Sheet and Cash Flow
Total Cash (mrq)
13.16B
Total Debt/Equity (mrq)
1,039.99%
Levered Free Cash Flow (ttm)
19.64B
Research Analysis: ABBV
View MoreCompany Insights: ABBV
ABBV does not have Company Insights
Research Reports: ABBV
View MoreDaily – Vickers Top Buyers & Sellers for 08/08/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
HOLD on Humira competition
AbbVie, a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. The company is based in suburban Chicago. The shares are a component of the S&P 500.
RatingPrice TargetThe board is green. Stocks are making a strong comeback after a wild ride this
The board is green. Stocks are making a strong comeback after a wild ride this week. The Mag7 are split, some up, some down. The big driver today is inflation data that is showing progress on prices continuing to track lower. The Personal Consumption Expenditures index came in at 2.5% in June, slightly below the 2.6% in May. Core PCE printed at 2.6% for June, unchanged from May. Next week is a biggie. The July Jobs report is due on Friday, four more of the Mag7 report - Apple, Amazon, Microsoft, and Meta, and oh, and there's a Fed rate meeting - though no rate move is widely expected.
AbbVie's Next Generation Immunology Drugs Are Offsetting the Biosimilar Pressures to Humira
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
RatingPrice Target